Area of research
Hepatology · Epidemiology
Research interest
Research interests include Liver Disease Diagnosis and Treatment, Hepatocellular Carcinoma Treatment and Prognosis, Liver Disease and Transplantation, and Hepatitis C virus research.
Serum procalcitonin: A novel tumor biomarker for diagnosis and disease monitoring in fibrolamellar hepatocellular carcinoma
Comparative evaluation of regression and machine-learning models for hepatocellular carcinoma risk stratification across diverse aetiologies
Detection of esophageal varices and prediction of hepatic decompensation in unresectable hepatocellular carcinoma using AI.
Long-term survival and cure fraction in patients with advanced hepatocellular carcinoma under immunotherapy in randomized controlled trials and real-world data.
Atezolizumab–bevacizumab in very elderly with hepatocellular carcinoma: Age alone is not a limiting factor except in ALBI grade 3
Prognosis of hepatocellular carcinoma in the French overseas territories and comparison with a tertiary center in mainland France
Real-world effectiveness and safety of bulevirtide monotherapy for up to 96 weeks in patients with HDV-related cirrhosis
Real-world effectiveness and safety of bulevirtide monotherapy for up to 96 weeks in patients with HDV-related cirrhosis.
Differences between hepatocellular carcinoma caused by alcohol and other aetiologies.
Value of non-invasive test dynamics in guiding HCC surveillance decisions after HCV cure in patients with cirrhosis
Value of non-invasive test dynamics in guiding HCC surveillance decisions after HCV cure in patients with cirrhosis.
Hepatopulmonary syndrome in patients with porto-sinusoidal vascular disorder: Characteristics and outcome
Utility of tumor and non-tumor biopsies during percutaneous radiofrequency ablation for hepatocellular carcinoma.
Reply to: "Male-to-female ratios in the risk of hepatocellular carcinoma: A nationwide study of Danish patients with viral or non-viral cirrhosis": Advocating for scalable etiology-agnostic HCC risk models for personalized HCC surveillance.
Associations between fruit and vegetable consumption and HCC occurrence in patients with cirrhosis.
MASLD-related HCC: Multicenter study comparing patients with and without cirrhosis.
Treatment with bulevirtide in HIV-infected patients with chronic hepatitis D: ANRS HD EP01 BuleDelta and compassionate cohort
Association of LI-RADS and Histopathologic Features with Survival in Patients with Solitary Resected Hepatocellular Carcinoma.
Treatment with bulevirtide in HIV-infected patients with chronic hepatitis D: ANRS HD EP01 BuleDelta and compassionate cohort.
Heterogeneity in adverse events related to atezolizumab-bevacizumab for hepatocellular carcinoma reported in real-world studies.
Prolonged survival in women with hepatocellular carcinoma: A French observational study.
Patient and physician expectations regarding disease and treatment of advanced HCC: The prospective PERCEPTION1 study
Molecular-based targeted therapies in patients with hepatocellular carcinoma and hepato-cholangiocarcinoma refractory to atezolizumab/bevacizumab.
Hepatocyte-derived biomarkers predict liver-related events at 2 years in Child-Pugh class A alcohol-related cirrhosis
Clinical, histological and molecular profiling of different stages of alcohol-related liver disease
Management of alcohol‐related liver disease: the French Association for the Study of the Liver and the French Alcohol Society clinical guidelines
Prediction of hepatocellular carcinoma in Hepatitis C patients with advanced fibrosis after sustained virologic response
Quality criteria for the measurement of liver stiffness.
Non-invasive diagnosis and follow-up of non-alcoholic fatty liver disease.
Non-invasive diagnosis and follow-up of primary sclerosing cholangitis